1. **Standing business**
   - Welcome & apologies
   - Declaration of potential or actual Conflict of Interest
   - Correspondence
   - Update from Secretariat

2. **Reviews of existing LSDP medicines**
   2.1 **TRANCHES 1 and 2**
   - Fabry disease draft report
   - Gaucher disease - update on progress
   - Idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis type II – update on progress
   - Alglucosidase alfa (Myozyme®) for treatment of Pompe disease – update on progress
   - Eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria – update on progress

   **TRANCHE 3 – consideration of draft Review Protocols**
   - Laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
   - Galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
   - Nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

3. **Applications for new LSDP medicines**
   Update from Secretariat on status of new LSDP medicine applications

4. **Other business**